This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
- Conditions
- Advanced or metastatic solid tumors
- Registration Number
- 2024-511503-41-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruitment ended
- Sex
- Not specified
- Target Recruitment
- 112
Not provided
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (14)
HELIOS Klinikum Berlin-Buch GmbH
🇩🇪Berlin, Germany
University Hospital Cologne AöR
🇩🇪Cologne, Germany
Universitaetsmedizin Goettingen
🇩🇪Goettingen, Germany
Universitaetsklinikum Tuebingen AöR
🇩🇪Tuebingen, Germany
Karolinska University Hospital
🇸🇪Solna, Sweden
UZ Leuven
🇧🇪Leuven, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪Sint-Lambrechts-Woluwe, Belgium
Med Polonia Sp. z o.o.
🇵🇱Poznan, Poland
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
🇵🇱Warsaw, Poland
Complexo Hospitalario Universitario De Santiago
🇪🇸Santiago De Compostela, Spain
Scroll for more (4 remaining)HELIOS Klinikum Berlin-Buch GmbH🇩🇪Berlin, GermanyPeter ReichardtSite contact+4930940154801peter.reichardt@helios-gesundheit.de